Kotryna Seip
- Post.Doc; PhD
- 2278 1861
Publications 2022
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208
Publications 2021
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol, 15 (8), 2026-2045
DOI 10.1002/1878-0261.12951, PubMed 33759347
EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition
Mol Cancer Res, 19 (9), 1546-1558
DOI 10.1158/1541-7786.MCR-20-0962, PubMed 34088869
Publications 2020
Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells
Sci Rep, 10 (1), 16992
DOI 10.1038/s41598-020-74083-z, PubMed 33046784
Publications 2019
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976
Publications 2018
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
Cancer Lett, 439, 1-13
DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588
Publications 2016
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Oncotarget, 7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352